Novo Nordisk A/S (NVO)
| Market Cap | 219.45B |
| Revenue (ttm) | 21.03B |
| Net Income (ttm) | 7.22B |
| Shares Out | 2.28B |
| EPS (ttm) | 3.08 |
| PE Ratio | 31.32 |
| Forward PE | 34.36 |
| Dividend | $1.31 (1.36%) |
| Ex-Dividend Date | Aug 16, 2021 |
| Volume | 2,463,889 |
| Open | 97.05 |
| Previous Close | 99.56 |
| Day's Range | 95.36 - 98.10 |
| 52-Week Range | 66.59 - 117.35 |
| Beta | 0.26 |
| Analysts | Hold |
| Price Target | 108.16 (+12.3%) |
| Earnings Date | Nov 5, 2021 |
About NVO
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration a...
Analyst Forecast
According to 3 analysts, the average rating for Novo Nordisk stock is "Hold." The 12-month stock price forecast is 108.16, which is an increase of 12.29% from the latest price.
News
Novo Nordisk announces settlement of securities lawsuit in Denmark
Bagsværd , De n mark, 14 January 202 2 – Novo Nordisk today announced that the company has settled a securities lawsuit in Denmark filed in August 2019. The settlement contains no admission of liability...
FDA Concerns At Catalent Site Spurred Novo Nordisk's Wegovy Supply Woes: Report
Last week, Catalent Inc (NYSE: CTLT) received an FDA write-up for its syringe filling facility in Belgium, "allegedly" the culprit behind supply shortage for Novo Nordisk A/S's (NYSE: NVO) obesity drug ...
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 10 January 202 2 – On 5 November 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Counci...
Novo Nordisk Shares Slump As Wegovy Hits US Supply Issues; Deutsche Bank Downgrades
Novo Nordisk A/S (NYSE: NVO) said that a contract manufacturer filling syringes for pens to inject Wegovy (semaglutide) had temporarily halted deliveries and manufacturing after issues relating to good ...
Novo Nordisk shares slump on U.S. supply challenges for obesity drug
Novo Nordisk shares fell 16% on Monday after the Danish drugmaker late on Friday announced that it will not be able to meet demand for its new weight-loss drug after supply issues in the United States.
Final Trades: WRK, NVO, LULU & TGT
The final trades of the week. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Steve Grasso, Jeff Mills and Nadine Terman.
Novo Nordisk announces supply challenges for Wegovy® in the US
Bagsværd , De n mark, 17 December 2021 – Novo Nordisk today announced that a contract manufacturer filling syringes for Wegovy ® pens for the US market has temporarily stopped deliveries and manufacturi...
DICERNA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of P...
NEW ORLEANS, Dec. 14, 2021 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Digital Behavioral Health Innovator Ksana Health Joins Novo Nordisk's Global Prevention Accelerator
EUGENE, Ore.--(BUSINESS WIRE)-- #BehavioralHealth--Ksana Health, a digital behavioral health company, today announced its selection by Novo Nordisk's Global Prevention Accelerator.
Novo Nordisk A/S: Share repurchase programme
Bagsværd , Denmark, 6 December 2021 – On 5 November 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Counci...
Final Trades: NVO, TSE, WMT & bitcoin
The traders offer their final trades of the week. With CNBC's Dominic Chu and the Fast Money traders, Tim Seymour, Steve Grasso, Brian Kelly and Nadine Terman.
Novo Nordisk announces impact from Volume Based Procurement for insulin in China
Bagsværd , De n mark, 26 November 2021 – Novo Nordisk today announced that the company has received the results from the Volume Based Procurement (VBP) tender for insulin in China. The Chinese National ...
Novo Nordisk (NVO) Set to Acquire Dicerna for $3.3 Billion
Novo Nordisk (NVO) inks agreement to acquire Dicerna for $3.3 billion. The company is looking to boost its RNAi research platform with this acquisition.
Dicerna Pharmaceuticals acquired by Novo Nordisk; Shares rocket 80%
Dicerna Pharmaceuticals (Nasdaq: DRNA) is a biopharma company that concentrates on developing RNAi therapeutics that announced that Novo Nordisk would acquire it for a total equity value of about $3.3 b...
Novo Nordisk Swallows Dicerna In $3.3B Buyout: All You Need To Know
Novo Nordisk A/S (NYSE: NVO) has agreed to acquire Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) for $38.25 per share in cash, representing a total equity value of $3.3 billion and a premium of 80% to Dice...
Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billion
(Reuters) -Danish drugmaker Novo Nordisk will buy Dicerna Pharmaceuticals Inc for $3.3 billion in cash, the U.S. drug developer said on Thursday.
Novo Nordisk strikes $3.3 billion to buy research partner Dicerna Pharmaceuticals
Novo Nordisk NVO, +0.37% NOVO.B, +0.69% said it's buying Dicerna Pharmaceuticals DRNA, -0.09% for $3.3 billion, or $38.25 per share in cash. Dicerna ended Wednesday at $21.28.
3 Big Pharma Outperformers to Watch Out For in the Near Term
Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.
Novo Nordisk (NVO) Gets Positive CHMP Opinion for Wegovy
The CHMP gives a positive opinion on, and recommends approval to Novo Nordisk's (NVO) Wegovy for chronic weight management in adults with obesity.
EMA Backs Approval Of Novo Nordisk's Ozempic 2mg Dose For Diabetes
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a label extension for Novo Nordisk A/S's (NYSE: NVO) Ozempic's new...
Trading in Novo Nordisk shares by board members, executives and associated persons on 5 November 2021
Bagsværd, Denmark, 8 November 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accorda...
Novo Nordisk A/S purchases B shares worth DKK 4,109 million from Novo Holdings A/S under the 2021 share repurchase pr...
Bagsværd , Denmark, 5 November 202 1 — Novo Nordisk A/S has today entered into an agreement to purchase 5,610,000 B shares of DKK 0.20 to a value of DKK 4,109 million from Novo Holdings A/S. This transa...
Trading in Novo Nordisk shares by board members, executives and associated persons on 3 November 2021
Bagsværd, Denmark, 4 November 202 1 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated perso...
Novo Nordisk's (NVO) Q3 Earnings and Sales Beat Estimates
Novo Nordisk (NVO) reports better-than-expected results for Q3. Sales are aided by growth in Diabetes and Obesity Care owing to higher GLP-1 revenues.